222 related articles for article (PubMed ID: 16230005)
1. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L
Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057
[TBL] [Abstract][Full Text] [Related]
5. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Cheung KL; Owers R; Robertson JF
Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Neven P; Paridaens R; Pelgrims G; Martens M; Bols A; Goeminne JC; Vindevoghel A; Demol J; Stragier B; De Greve J; Fontaine C; Van Den Weyngaert D; Becquart D; Borms M; Cocquyt V; Van Den Broecke R; Selleslags J; Awada A; Dirix L; Van Dam P; Azerad MA; Vandenhoven G; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2008 May; 109(1):59-65. PubMed ID: 17592772
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
9. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
12. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R; Mlineritsch B; Gnant M; Niernberger T; Pluschnig U; Greil R; Wenzel C; Sevelda P; Thaler J; Rudas M; Pober M; Zielinski CC; Steger GG;
Breast Cancer Res Treat; 2009 May; 115(2):373-80. PubMed ID: 18661231
[TBL] [Abstract][Full Text] [Related]
13. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Abram P; Maass N; Rea D; Simon SD; Steger GG
Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Howell A
Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Ishida N; Araki K; Sakai T; Kobayashi K; Kobayashi T; Fukada I; Hosoda M; Yamamoto M; Ichinokawa K; Takahashi S; Iwase T; Ito Y; Yamashita H
Breast Cancer; 2016 Jul; 23(4):617-23. PubMed ID: 25896598
[TBL] [Abstract][Full Text] [Related]
19. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.
Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Mader RM; Gnant M; Jakesz R; Rudas M; Zielinski CC; Steger GG
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4435-9. PubMed ID: 17671127
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
